WEDI report to serve as new health IT roadmap

Patient engagement, payment models, data harmonization and exchange and innovative encounter models are the four critical areas for the next decade of health IT, according to the Workgroup for Electronic Data Interchange (WEDI) Foundation's report.

The report is the culmination of a nine-month, public-private effort with more than 200 subject matter expert volunteers and is intended to serve as a new roadmap for health IT.

”Like the WEDI report that I initiated in 1993 that became the roadmap for electronic business solutions for healthcare in the 1990s, the 2013 WEDI Report and recommendations will serve as the roadmap that will lead to greater efficiency and improved healthcare delivery in the years ahead,” said Louis W. Sullivan, MD, WEDI founder and honorary chair of the 2013 WEDI Report executive steering committee. “I regarded the implementation of the 1993 WEDI Report roadmap as a civic duty for its time, and it is my hope that the healthcare industry will adopt that same spirit for the 2013 WEDI Report recommendations.”

Read the full report.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.